Regulatory
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 18, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 15, 2020.
Following a study that raises concerns about the accuracy of Abbott’s rapid COVID-19 test for detecting the virus, the U.S. Food and Drug Administration (FDA) announced it will investigate the claims found in a New York University-related study as the company updates its guidance on the ID NOW test.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 14, 2020.
The designation will expedite regulatory review of the medication should it prove to be safe and effective.
This morning, the companies announced the regulatory agency issued a Refusal to File letter regarding the BLA for idecabtagene vicleucel (ide-cel; bb2121) for patients with heavily pretreated relapsed and refractory multiple myeloma.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 13, 2020.
A new report released on Tuesday by GlobalData suggested that there was a 16% decrease in new drug approvals (NDAs) by the U.S. Food and Drug Administration last year.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 12, 2020.
Approval of Abbott’s latest antibody test comes days after the FDA tightened its rules regarding the regulatory requirement for them.
PRESS RELEASES